Pharmafile Logo
Pharmafocus logo
Advanced Search

Ninlaro

Showing 6 posts of 6 posts found.

takeda_usa_pharmaceuticals_u

Takeda’s Ninlaro combo fails to hit main goal in newly diagnosed, transplant ineligible multiple myeloma

March 11, 2020
Research and Development, Sales and Marketing Ninlaro, Takeda, multiple myeloma, pharma

Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed …

News

Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma

November 8, 2019
Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …

News
takeda_usa_pharmaceuticals_u

Takeda’s Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma

July 12, 2018
Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma

After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 …

News

Takeda’s Ninlaro knocked back by NICE for second time

September 5, 2017
Research and Development, Sales and Marketing Ninlaro, Takeda, biotech, drugs, pharma, pharmaceutical

NICE has revealed that the outcome of its consultation process for Ninlaro (ixazomib), Takeda’s treatment for relapsed or refractory multiple …

News
Ninlaro

Takeda in myeloma research drive

January 14, 2016
Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma

Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …

News
Ninlaro

Takeda’s Ninlaro extends myeloma survival in trial

December 7, 2015
Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma

Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024